A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures-Reference-Cited by-同舟云学术

A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures

Published:2021-12-01 Issue:6 Volume:6 Page:528-536
ISSN:2578-5125
Container-title:Cannabis and Cannabinoid Research
language:en
Short-container-title:Cannabis and Cannabinoid Research

Author:

Brodie Martin J.¹,Czapinski Piotr²,Pazdera Ladislav³,Sander Josemir W.⁴⁵⁶,Toledo Manuel⁷,Napoles Mariana⁸,Sahebkar Farhad⁹,Schreiber Ashley⁸,Nezadal Tomas,Slonkova Jana,Altman Anna,Füle Kálmán,Horváth Ágnes,Kelemen Anna,Komoly Sámuel,Banach Marta,Kurkowska-Jastrzebska Iwona,Lisewski Paweł,Falip Merce,Rocamora Rodrigo,Bagary Manny,

Affiliation:

1. Epilepsy Unit, University of Glasgow, Glasgow, United Kingdom.

2. Epilepsy and Migraine Treatment Center, Krakow, Poland.

3. Vestra Clinics - Dedicated Research Clinics, Rychnov nad Kneznou, Czech Republic.

4. NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom.

5. Chalfont Centre for Epilepsy, Chalfont St. Peter, United Kingdom.

6. Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, Netherlands.

7. Epilepsy Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain.

8. GW Research Ltd, Cambridge, United Kingdom.

9. Greenwich Biosciences, Inc., Carlsbad, California, USA.

Publisher

Mary Ann Liebert Inc